Theriva Biologics, Inc. - 8-K Filing
Theriva Biologics announced authorization from Spain's AEMPS to initiate a Phase IIa clinical trial, VIRAGE2, evaluating more frequent dosing of VCN-01 (zabilugene almadenorepvec) in combination with gemcitabine/nab-paclitaxel for newly-diagnosed metastatic pancreatic cancer. The study aims to assess the feasibility and tolerability of administering at least three doses of VCN-01 every two months, building on prior results showing improved survival outcomes when using repeated dosing. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TOVX